about
Divergent solution-phase synthesis of diarylpyrimidine libraries as selective A3 adenosine receptor antagonists.MIND-BEST: Web server for drugs and target discovery; design, synthesis, and assay of MAO-B inhibitors and theoretical-experimental study of G3PDH protein from Trichomonas gallinae.NL MIND-BEST: a web server for ligands and proteins discovery--theoretic-experimental study of proteins of Giardia lamblia and new compounds active against Plasmodium falciparum.ANN multiplexing model of drugs effect on macrophages; theoretical and flow cytometry study on the cytotoxicity of the anti-microbial drug G1 in spleen.TOPS-MODE model of multiplexing neuroprotective effects of drugs and experimental-theoretic study of new 1,3-rasagiline derivatives potentially useful in neurodegenerative diseases.Ugi-based approaches to quinoxaline libraries.Structure-based design of new KSP-Eg5 inhibitors assisted by a targeted multicomponent reaction.Review of synthesis, biological assay and QSAR studies of β-secretase inhibitors.Patents of bio-active compounds based on computer-aided drug discovery techniques.Multi-Target Mining of Alzheimer Disease Proteome with Hansch's QSBR-Perturbation Theory and Experimental-Theoretic Study of New Thiophene Isosters of Rasagiline.Synthesis by microwave-assisted 1,3-dipolar cycloaddition of 1,2,3-triazole 1'-homo-3'-isoazanucleosides and evaluation of their anticancer activity.Review of Theoretical Models to Study Natural Products with Antiprotozoal Activity.Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists.Synthesis and pharmacological evaluation of novel 1,3,8- and 1,3,7,8-substituted xanthines as adenosine receptor antagonists.Discovery of 3,4-Dihydropyrimidin-2(1H)-ones As a Novel Class of Potent and Selective A2B Adenosine Receptor Antagonists.Synthesis and pharmacological evaluation of novel 1- and 8-substituted-3-furfuryl xanthines as adenosine receptor antagonists.Brain-inspired cheminformatics of drug-target brain interactome, synthesis, and assay of TVP1022 derivatives.Probing the anticancer activity of nucleoside analogues: a QSAR model approach using an internally consistent training set.Synthesis and QSAR study of the anticancer activity of some novel indane carbocyclic nucleosides.Development of Fluorescent Probes that Target Serotonin 5-HT2B Receptors.Methyl 2-diphenyl-phosphor-yloxy-2-aza-bicyclo-[2.2.1]hept-5-ene-3-exo-carboxyl-ate.Model for high-throughput screening of multitarget drugs in chemical neurosciences: synthesis, assay, and theoretic study of rasagiline carbamates.Synthesis, antiviral and cytostatic activities of carbocyclic nucleosides incorporating a modified cyclopentane ring. Part 2: Adenosine and uridine analogues.Prediction of multi-target networks of neuroprotective compounds with entropy indices and synthesis, assay, and theoretical study of new asymmetric 1,2-rasagiline carbamates.Synthesis and pharmacological evaluation of novel substituted 9-deazaxanthines as A2B receptor antagonists.New carbocyclic nucleosides derived from indan.Synthesis and allosteric modulation of the dopamine receptor by peptide analogs of L-prolyl-L-leucyl-glycinamide (PLG) modified in the L-proline or L-proline and L-leucine scaffolds.Selective and potent adenosine A3 receptor antagonists by methoxyaryl substitution on the N-(2,6-diarylpyrimidin-4-yl)acetamide scaffold.Using entropy of drug and protein graphs to predict FDA drug-target network: theoretic-experimental study of MAO inhibitors and hemoglobin peptides from Fasciola hepatica.1,3-dialkyl-8-N-substituted benzyloxycarbonylamino-9-deazaxanthines as potent adenosine receptor ligands: Design, synthesis, structure-affinity and structure-selectivity relationships.Synthesis of novel purinyl-1'-homocarbanucleosides based on a cyclopenta[b]pyrazine system.Click chemistry approach to assembly proline mimetic libraries containing 1,4-substituted 1,2,3-triazoles.2-Substituted 4-, 5-, and 6-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones and 2-substituted 4,5-bis[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones as potent platelet aggregation inhibitors: design, synthesis, and SAR studies.Entropy model for multiplex drug-target interaction endpoints of drug immunotoxicity.2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins.New hexahydrocarbazoles and spiro indoles, and their affinity for D2 dopamine and 5-HT2A serotonin receptors.Novel l-prolyl-l-leucylglycinamide (PLG) tripeptidomimetics based on a 2-azanorbornane scaffold as positive allosteric modulators of the D2R.Multicomponent Assembly of the Kinesin Spindle Protein Inhibitor CPUYJ039 and Analogues as Antimitotic Agents.Enantiospecific Recognition at the A2B Adenosine Receptor by Alkyl 2-Cyanoimino-4-substituted-6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxylates.3D MI-DRAGON: new model for the reconstruction of US FDA drug- target network and theoretical-experimental studies of inhibitors of rasagiline derivatives for AChE.
P50
Q33453741-12A155B7-AF73-4342-BD88-0321E59BBC0EQ33780103-F53D2045-1C3B-4D86-A8DA-480A7D0646F4Q33806779-2D1A78C9-4308-4AB1-B6EB-C175DF87E6C4Q34415311-E6BC6DF6-95E1-4F4B-903A-13EDBDE7AD5FQ34588832-945A1760-1ADA-4CDF-920D-B5DC7A92BAAEQ35163549-8A709CF6-6FE3-4AF7-A307-E63BCC5D0264Q35190903-C3F3AD6E-40DA-4F35-9693-3108862689DCQ37952345-F8A034D6-349C-486A-B43C-028D2FBD6D5CQ38070554-267A366E-3823-40F8-8991-69BA6EFB8EE6Q38621572-F0F61864-D702-49CA-897A-4487844F9A19Q38869515-FC0DC450-86E2-4398-8FCE-36DF051C08C7Q39053585-938A9024-E0EF-4B11-9E50-39B2470CAAA6Q39615457-142DD2D3-78D3-4289-A391-CF8B1AA7C6C3Q39742826-87E4255B-8323-4C5D-880F-4CCA8DB5C69DQ39775269-007955AA-18B7-4ED6-A488-B7A32E67BB1DQ39812376-C8D4C325-D714-46B7-B9BC-13ED66F7167EQ40154011-66DCDA99-F713-4681-B200-8D039AC51228Q40236796-026BE3B5-383C-496A-A25F-880A7C3C527BQ40618898-3DC1B0D4-A980-4DBA-8687-61D77F508BF4Q41538383-9A4E4065-51A7-40D5-B1D5-1C3D0666F3DCQ42034328-B319B3B3-BEA1-4D1F-9E23-C9DA367E54E7Q42043842-1690BE5B-70E9-4C1D-A010-2F220E2D62CBQ42540287-D9ED0402-B40C-40B9-947C-928CB4CB5CDCQ42920103-843DD0C1-5819-48AB-A6A4-A5A9E1896236Q43108307-FC54EE09-76FC-474D-B740-548995D662F8Q43741691-D3322C19-6F81-4651-9E1C-D1F1A47E5584Q44470100-14F8970C-14B1-459C-A175-3EC3688AE7BCQ45783242-0C25A5F0-56CD-4B27-B412-1D33E7570E85Q45962192-08638EF0-C31C-46F0-848C-1E0E2232FE69Q46034571-EFBF18A8-E1D9-4EA7-88C3-742F6EC9BC9AQ46615757-FC4BED3D-9EC5-4E89-99E0-E49FE0976B62Q46620710-B6618991-7D8B-45B8-8246-D5E0BF6C2624Q46870732-382A09FC-717F-4B42-A39F-889314C95575Q47929423-437ACCE8-A587-4DF2-A5BB-9A8A215617D1Q47992710-83C3A4F9-B7D7-464E-8B9E-AE515F0CA226Q48144370-3CDDF3AC-DF9F-4951-9B41-6454A98812B2Q48234703-FA1BE891-114F-4AC4-927F-6646346A1805Q48298446-2B0715D8-75C1-48A3-A839-F699F3F0772AQ48336780-0BC386B2-A2F9-41B3-88EF-3C37AB6AFD4AQ51315190-B9815E11-0E83-4B61-8145-E78A0D4DD251
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Xerardo Garcia-mera
@ast
Xerardo Garcia-mera
@en
Xerardo Garcia-mera
@es
Xerardo Garcia-mera
@nl
Xerardo Garcia-mera
@sl
type
label
Xerardo Garcia-mera
@ast
Xerardo Garcia-mera
@en
Xerardo Garcia-mera
@es
Xerardo Garcia-mera
@nl
Xerardo Garcia-mera
@sl
prefLabel
Xerardo Garcia-mera
@ast
Xerardo Garcia-mera
@en
Xerardo Garcia-mera
@es
Xerardo Garcia-mera
@nl
Xerardo Garcia-mera
@sl
P1053
E-4294-2012
P106
P1153
6701392096
P21
P31
P3829
P496
0000-0001-5218-6351